Gold, sulphur and mercurial formulations in Indian alchemy are consumed in conjunction with suitable adjuvant for the better result of their synergistic action, reduced toxicity and consequently boosting their bioavailability via the body's cells due to their nano size resulting in improved effectiveness. Poorna chandrodaya chendooram is a well-known mercurial mixture containing gold and sulphur that has traditionally been used to treat a variety of diseases including tuberculosis, jaundice, fever, rat-bite, malignant ulcer, sprue, and male sterility. Fel bovinum purifactum ( Gorochanai ) is an expectorant. It is used to treat fever, nausea, dyspnea, general weakness, headache, and other symptoms in children. Gorochanai pill relieves asthma, hiccups, cough, and Hemiplegia. It acts as a bronchodilator. The second wave mutant virus has better transmission potential and a shorter incubation period than the first wave. Some diabetic patients treated for SARS-CoV-2 with high dose corticosteroids had a decrease in angioinvasive maxillofacial fungal infections (Mucormycosis). Without using synthetic steroids and with optimum oxygen support, this case report emphasises the therapeutic success of administering Poorna chandirodayam and Gorojanai mathirai together with herbal and herbomineral Siddha formulations as a supplementary when required in the early inflammatory phase of COVID-19 infection and hypoxic situation. 5 patients with the laboratory-confirmed diagnosis of coronavirus (SARS- CoV2) infection admitted in the approved Siddha Covid hospital have been involved in the study. When the drug is properly prepared and given in a safe dosage during the duration of treatment there will not be any side effects. Metal-based medications Poorna chandirodayam and Gorojanai mathirai been demonstrated through these case series to be safe and useful in COVID19.

Aims: To evaluate clinical validation, safety assessment and efficacy of Siddha line of treatment in COVID-19 patients. Presentation of the Case: Open labelled, interventional, prospective cohort study conducted in Covid ward, Kokila Siddha Hospital and Research Centre, Madurai between June and Aug 2021. Among 22 registered in the trial 5 (22.72%) developed breathing difficulty, treated with oxygen support, 10 (45.5%) were male, 12 (54.5%) were female. At the time of admission, maximum 9 (40.9 %) had fever, followed by dry cough 18 (81.8%), dyspnea 8 (36.4%), malaise 16 (72.7%), anorexia 8 (36.4%), headache 4 (18.2%), Type-2DM 5 (23%), and 2 (9%) had hypertension as comorbidity. Hematology, LFT, RFT, D-Dimer, PTT, CRP were taken before and after 5 days of treatment. Discussion: The mean hospital stay was 7 days and discharged on a minimum of 4th day and a maximum of 16th day. The mean hospital stay for hypoxic patients was 10 days. Paired sample test analysis has been carried out to find a significant difference in the counts of lymphocytes, ESR, CRP and PTT after the administration of the intervention. Conclusion: The medications chosen according to the pathology of Kaba suram and administered starting on first day of admission, depending on the stage and severity of the infection. Patients were provided with appropriate food, exercise, therapy in conjunction with medications and found the patient's condition has not deteriorated further. It is reasonable to conclude that the treatment of COVID-19 with selective Siddha medications stopped the disease progress more critical.